HQOL measure | Mean (SD) | Mean change vs. Baseline (SE) | P-value trend | ICC (95% CI) |
---|---|---|---|---|
KCCQ | ||||
 Physical limitation |  |  |  | 0.16 (0.05, 0.41) |
  Baseline | 12.6 (18.9) | – | – |  |
  Month 1 | 41.9 (28.9) | −29.4 (3.0) | <  0.001 |  |
  Month 3 | 41.2 (25.9) | −28.8 (3.5) | <  0.001 |  |
 Symptom stability |  |  |  | 0.24 (0.08, 0.53) |
  Baseline | 51.5 (21.1) | – | – |  |
  Month 1 | 48.5 (20.7) | 2.9 (2.9) | 0.450 |  |
  Month 3 | 46.1 (21.7) | 5.4 (3.7) | 0.142 |  |
 Symptom frequency |  |  |  | 0.14 (0.03, 0.45) |
  Baseline | 38.4 (22.9) | – | – |  |
  Month 1 | 47.3 (30.9) | −9.1 (3.5) | 0.046 |  |
  Month 3 | 52.9 (32.0) | −14.5 (4.2) | 0.003 |  |
 Symptom burden |  |  |  | 0.08 (0.01, 0.56) |
  Baseline | 40.6 (24.7) | – | – |  |
  Month 1 | 42.7 (33.3) | −8.7 (3.8) | 0.046 |  |
  Month 3 | 52.4 (35.3) | −18.5 (4.7) | 0.001 |  |
 Total symptom score |  |  |  | 0.11 (0.02, 0.48) |
  Baseline | 39.5 (23.8) | – | – |  |
  Month 1 | 45.0 (31.9) | −8.8 (3.6) | 0.046 |  |
  Month 3 | 52.7 (33.4) | −16.5 (4.4) | 0.002 |  |
 Self-efficacy |  |  |  | 0.45 (0.29, 0.62) |
  Baseline | 58.7 (21.7) | – | – |  |
  Month 1 | 31.5 (24.3) | 27.2 (3.1) | <  0.001 |  |
  Month 3 | 25.0 (24.4) | 33.6 (3.8) | <  0.001 |  |
 Quality of life |  |  |  | 0.14 (0.03, 0.44) |
  Baseline | 23.1 (16.1) | – | – |  |
  Month 1 | 14.5 (22.7) | 8.7 (2.5) | 0.005 |  |
  Month 3 | 13.1 (22.2) | 10.2 (2.9) | 0.024 |  |
 Social limitation |  |  |  | 0.13 (0.03, 0.41) |
  Baseline | 11.9 (18.7) | – | – |  |
  Month 1 | 13.0 (28.9) | −1.2 (3.0) | 0.008 |  |
  Month 3 | 13.8 (26.9) | −2.0 (3.5) | 0.905 |  |
 Overall summary score |  |  |  | 0.13 (0.03, 0.43) |
  Baseline | 21.8 (15.8) | – | – |  |
  Month 1 | 28.6 (23.4) | −7.7 (2.5) | 0.008 |  |
  Month 3 | 30.2 (21.4) | −9.3 (2.9) | 0.002 |  |
 Clinical summary score |  |  |  | 0.16 (0.04, 0.44) |
  Baseline | 26.0 (18.6) | – | – |  |
  Month 1 | 43.4 (25.3) | −19.2 (2.8) | <  0.001 |  |
  Month 3 | 46.9 (24.9) | −22.6 (3.4) | <  0.001 |  |